30th October, 2023
Lunit to support MD Anderson researchers studying immune phenotype biomarkers for pembrolizumab treatment response
Lunit AI-powered TIL analyzer, Lunit SCOPE IO
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck's (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types. The project will use Lunit's proprietary AI solution for tissue data analysis, Lunit SCOPE IO.
Medtech Special
Artificial Intelligence Breakthroughs
Robots In Medtech
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer